Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Solid Biosciences Inc (SLDB)

Solid Biosciences Inc (SLDB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 308,829
  • Shares Outstanding, K 110,296
  • Annual Sales, $ 0 K
  • Annual Income, $ -88,290 K
  • 60-Month Beta 0.95
  • Price/Sales 31.64
  • Price/Cash Flow N/A
  • Price/Book 1.30
Trade SLDB with:

Options Overview

Details
  • Implied Volatility 115.34%
  • Historical Volatility 42.97%
  • IV Percentile 27%
  • IV Rank 11.30%
  • IV High 396.88% on 09/29/20
  • IV Low 79.47% on 07/20/21
  • Put/Call Vol Ratio 0.02
  • Today's Volume 200
  • Volume Avg (30-Day) 121
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 2,117
  • Open Int (30-Day) 1,310

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.20
  • Number of Estimates 4
  • High Estimate -0.17
  • Low Estimate -0.24
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +54.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.53 +5.34%
on 09/14/21
2.89 -7.94%
on 09/07/21
+0.19 (+7.89%)
since 08/20/21
3-Month
2.37 +12.45%
on 08/20/21
4.14 -35.63%
on 06/24/21
-1.25 (-31.84%)
since 06/18/21
52-Week
1.93 +38.08%
on 09/24/20
11.58 -76.99%
on 02/24/21
+0.22 (+9.22%)
since 09/18/20

Most Recent Stories

More News
Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

- Functional and patient-reported outcomes data for the first three patients in the high-dose (2E14 vg/kg) cohort (Patients 4-6) 1.5 years post-dosing to be presented at the World Muscle Society 2021 Virtual...

SLDB : 2.66 (-5.00%)
Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, Ph.D., Chief Operating...

SLDB : 2.66 (-5.00%)
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

SRPT : 85.67 (-0.82%)
ABBV : 106.40 (-1.23%)
QURE : 36.62 (-0.52%)
VYGR : 2.97 (-4.50%)
RGNX : 43.58 (-3.24%)
SLDB : 2.66 (-5.00%)
MGTX : 12.88 (-4.66%)
Solid Biosciences to Present at the 11th Annual World Orphan Drug Congress USA 2021

- Chief Operating Officer to discuss company's advanced AAV gene therapy manufacturing capabilities and best practices for orphan drug development -

SLDB : 2.66 (-5.00%)
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Finance

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its...

SLDB : 2.66 (-5.00%)
Solid Biosciences Announces Appointment of Michael Inbar, CPA, MBA, as Senior Vice President, Finance

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Michael Inbar, CPA, MBA, has joined...

XLRN : 139.55 (+1.42%)
SLDB : 2.66 (-5.00%)
Solid Biosciences Inc. (SLDB) Reports Q2 Loss, Tops Revenue Estimates

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 5.56% and 14.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

SLDB : 2.66 (-5.00%)
Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results

- Clinical activities underway to advance patient dosing in IGNITE DMD; next patient dosing anticipated in Q4 2021 -

SLDB : 2.66 (-5.00%)
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical Development

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to...

SLDB : 2.66 (-5.00%)
Solid Biosciences Strengthens Management Team to Advance Programs for Duchenne Muscular Dystrophy

-Additional expertise expected to support attainment of key corporate goals-

SLDB : 2.66 (-5.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001,...

See More

Key Turning Points

3rd Resistance Point 3.02
2nd Resistance Point 2.92
1st Resistance Point 2.86
Last Price 2.66
1st Support Level 2.69
2nd Support Level 2.59
3rd Support Level 2.53

See More

52-Week High 11.58
Fibonacci 61.8% 7.89
Fibonacci 50% 6.76
Fibonacci 38.2% 5.62
Last Price 2.66
52-Week Low 1.93

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar